Close

GW Pharma (GWPH) Announces Positive Data from Second Epidiolex Phase 3 as LGS Treatment

September 26, 2016 6:57 AM EDT Send to a Friend
GW Pharmaceuticals plc (Nasdaq: GWPH) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login